196 related articles for article (PubMed ID: 33810334)
1. Aminopeptidase Expression in Multiple Myeloma Associates with Disease Progression and Sensitivity to Melflufen.
Miettinen JJ; Kumari R; Traustadottir GA; Huppunen ME; Sergeev P; Majumder MM; Schepsky A; Gudjonsson T; Lievonen J; Bazou D; Dowling P; O Gorman P; Slipicevic A; Anttila P; Silvennoinen R; Nupponen NN; Lehmann F; Heckman CA
Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33810334
[TBL] [Abstract][Full Text] [Related]
2. Melflufen, a peptide-conjugated alkylator, is an efficient anti-neo-plastic drug in breast cancer cell lines.
Schepsky A; Traustadottir GA; Joelsson JP; Ingthorsson S; Kricker J; Bergthorsson JT; Asbjarnarson A; Gudjonsson T; Nupponen N; Slipicevic A; Lehmann F; Gudjonsson T
Cancer Med; 2020 Sep; 9(18):6726-6738. PubMed ID: 32717133
[TBL] [Abstract][Full Text] [Related]
3. Novel Peptide-drug Conjugate Melflufen Efficiently Eradicates Bortezomib-resistant Multiple Myeloma Cells Including Tumor-initiating Myeloma Progenitor Cells.
Byrgazov K; Besse A; Kraus M; Slipicevic A; Lehmann F; Driessen C; Besse L
Hemasphere; 2021 Jul; 5(7):e602. PubMed ID: 34136753
[TBL] [Abstract][Full Text] [Related]
4. Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma.
Mateos MV; Bladé J; Bringhen S; Ocio EM; Efebera Y; Pour L; Gay F; Sonneveld P; Gullbo J; Richardson PG
J Clin Med; 2020 Sep; 9(10):. PubMed ID: 32992506
[TBL] [Abstract][Full Text] [Related]
5. Melflufen for the treatment of multiple myeloma.
Ocio EM; Nadeem O; Schjesvold F; Gay F; Touzeau C; Dimopoulos MA; Richardson PG; Mateos MV
Expert Rev Clin Pharmacol; 2022 Apr; 15(4):371-382. PubMed ID: 35723075
[TBL] [Abstract][Full Text] [Related]
6. Targeting aggressive osteosarcoma with a peptidase-enhanced cytotoxic melphalan flufenamide.
Byrgazov K; Anderson C; Salzer B; Bozsaky E; Larsson R; Gullbo J; Lehner M; Lehmann F; Slipicevic A; Kager L; Fryknäs M; Taschner-Mandl S
Ther Adv Med Oncol; 2020; 12():1758835920937891. PubMed ID: 32774473
[TBL] [Abstract][Full Text] [Related]
7. Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study.
Richardson PG; Bringhen S; Voorhees P; Plesner T; Mellqvist UH; Reeves B; Paba-Prada C; Zubair H; Byrne C; Chauhan D; Anderson K; Nordström E; Harmenberg J; Palumbo A; Sonneveld P
Lancet Haematol; 2020 May; 7(5):e395-e407. PubMed ID: 32213344
[TBL] [Abstract][Full Text] [Related]
8. Melflufen - a peptidase-potentiated alkylating agent in clinical trials.
Wickström M; Nygren P; Larsson R; Harmenberg J; Lindberg J; Sjöberg P; Jerling M; Lehmann F; Richardson P; Anderson K; Chauhan D; Gullbo J
Oncotarget; 2017 Sep; 8(39):66641-66655. PubMed ID: 29029544
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and Metabolism of Melflufen, an Alkylating Peptide-Drug Conjugate, in Patients with Relapsed Refractory Multiple Myeloma.
Huledal G; Ruiz-Garcia A; Kawakatsu S; Wang X; Sjöberg P; Gullbo J; Pekar D; Norin S; Jerling M
J Clin Pharmacol; 2024 Feb; 64(2):240-252. PubMed ID: 37752623
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo activity of melflufen (J1)in lymphoma.
Delforoush M; Strese S; Wickström M; Larsson R; Enblad G; Gullbo J
BMC Cancer; 2016 Apr; 16():263. PubMed ID: 27044263
[TBL] [Abstract][Full Text] [Related]
11. The Peptide-Drug Conjugate Melflufen Modulates the Unfolded Protein Response of Multiple Myeloma and Amyloidogenic Plasma Cells and Induces Cell Death.
Flanagan K; Kumari R; Miettinen JJ; Haney SL; Varney ML; Williams JT; Majumder MM; Suvela M; Slipicevic A; Lehmann F; Nupponen NN; Holstein SA; Heckman CA
Hemasphere; 2022 Mar; 6(3):e687. PubMed ID: 35243210
[TBL] [Abstract][Full Text] [Related]
12. OCEAN: a randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myeloma.
Schjesvold F; Robak P; Pour L; Aschan J; Sonneveld P
Future Oncol; 2020 Apr; 16(11):631-641. PubMed ID: 32141766
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo anti-leukemic activity of the peptidase-potentiated alkylator melflufen in acute myeloid leukemia.
Strese S; Hassan SB; Velander E; Haglund C; Höglund M; Larsson R; Gullbo J
Oncotarget; 2017 Jan; 8(4):6341-6352. PubMed ID: 27974676
[TBL] [Abstract][Full Text] [Related]
14. Positioning of aminopeptidase inhibitors in next generation cancer therapy.
Hitzerd SM; Verbrugge SE; Ossenkoppele G; Jansen G; Peters GJ
Amino Acids; 2014 Apr; 46(4):793-808. PubMed ID: 24385243
[TBL] [Abstract][Full Text] [Related]
15. The novel alkylating prodrug melflufen (J1) inhibits angiogenesis in vitro and in vivo.
Strese S; Wickström M; Fuchs PF; Fryknäs M; Gerwins P; Dale T; Larsson R; Gullbo J
Biochem Pharmacol; 2013 Oct; 86(7):888-95. PubMed ID: 23933387
[TBL] [Abstract][Full Text] [Related]
16. First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies.
Berglund Å; Ullén A; Lisyanskaya A; Orlov S; Hagberg H; Tholander B; Lewensohn R; Nygren P; Spira J; Harmenberg J; Jerling M; Alvfors C; Ringbom M; Nordström E; Söderlind K; Gullbo J
Invest New Drugs; 2015 Dec; 33(6):1232-41. PubMed ID: 26553306
[TBL] [Abstract][Full Text] [Related]
17. Methionine Aminopeptidase 2 as a Potential Therapeutic Target for Human Non-Small-Cell Lung Cancers.
Shimizu H; Yamagishi S; Chiba H; Ghazizadeh M
Adv Clin Exp Med; 2016; 25(1):117-28. PubMed ID: 26935506
[TBL] [Abstract][Full Text] [Related]
18. Aminopeptidase inhibition as a targeted treatment strategy in myeloma.
Moore HE; Davenport EL; Smith EM; Muralikrishnan S; Dunlop AS; Walker BA; Krige D; Drummond AH; Hooftman L; Morgan GJ; Davies FE
Mol Cancer Ther; 2009 Apr; 8(4):762-70. PubMed ID: 19372548
[TBL] [Abstract][Full Text] [Related]
19. Methionine aminopeptidase-2 regulates human mesothelioma cell survival: role of Bcl-2 expression and telomerase activity.
Catalano A; Romano M; Robuffo I; Strizzi L; Procopio A
Am J Pathol; 2001 Aug; 159(2):721-31. PubMed ID: 11485930
[TBL] [Abstract][Full Text] [Related]
20. Preclinical activity of melflufen (J1) in ovarian cancer.
Carlier C; Strese S; Viktorsson K; Velander E; Nygren P; Uustalu M; Juntti T; Lewensohn R; Larsson R; Spira J; De Vlieghere E; Ceelen WP; Gullbo J
Oncotarget; 2016 Sep; 7(37):59322-59335. PubMed ID: 27528037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
